think28m
The winners and losers of Biden’s plans to expand coverage of weight-loss drugs
The winners and losers of Biden’s plans to expand coverage of weight-loss drugs US President Joe Biden wants to expand the ...
European pharma’s growth prescription: pivot to US
The biggest threat for European pharmaceutical groups currently comes from the United States. President-elect Donald Trump ...
Scandasia.com4h
Novo Nordisk expands footprint in China with recruitment shift
Novo Nordisk shifts its recruitment focus to China, expanding operations to meet rising demand for Ozempic and Wegovy in the ...
Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack
Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...
Amgen's Phase 2 Results Were Not Bad, Don't Let Mr. Market Fool You
Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.
The Ultimate Pharmaceutical Stock to Buy With $1,000 Right Now
Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...